CLL Society has been receiving multiple questions surrounding Evusheld and the newly recommended second booster dose (fifth dose in total) for all individuals who are immunocompromised. These new recommendations are applicable to everyone with CLL/SLL.
In a pandemic with scarce resources, governments, medical institutions, and healthcare providers have had to make decisions and/or policies about allocating potentially lifesaving therapies among the many outpatients who might benefit from them.
At the annual meeting of the American Society of Hematology (ASH) 2021, Dr. Brian Koffman interviewed Dr. Larry Saltzman, a Family Physician and Executive Research Director of the Leukemia and Lymphoma Society. They discussed the benefits of a “booster” vaccine dose for blood cancer patients.
CLL Society support group’s facilitator, Jim Werner PhD, MSSA, of Case Western Reserve University in Cleveland, Ohio, put together this update on COVID-19 in January 2022.
In addition to having the COVID-19 Action Plan complete, it is encouraged to prepare for isolation by gathering a two-week supply of the following items:
We are going through a needless tragedy that will only worsen since Congress elected not to fund any more Evusheld. As a result, the already inadequate supplies will dwindle even more.
CLL Society is working to right the ship, but in the meantime, if you are considering getting Evusheld, it makes sense to not delay. Not that you need to panic. There are many thousands of doses out there now and more coming, albeit at a slower rate. But the